219 related articles for article (PubMed ID: 12037505)
21. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
22. Type 2 diabetes management: a comprehensive clinical review of oral medications.
Quillen DM; Kuritzky L
Compr Ther; 2002; 28(1):50-61. PubMed ID: 11894443
[TBL] [Abstract][Full Text] [Related]
23. Seeking sweet relief for diabetes.
Dove A
Nat Biotechnol; 2002 Oct; 20(10):977-81. PubMed ID: 12355109
[No Abstract] [Full Text] [Related]
24. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
25. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
26. Diabetes mellitus. Medication update.
Slagle M
South Med J; 2002 Jan; 95(1):50-5. PubMed ID: 11827245
[No Abstract] [Full Text] [Related]
27. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
28. Follow-up of intensive glucose control in type 2 diabetes.
Mühlhauser I
N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
[No Abstract] [Full Text] [Related]
29. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
30. A miracle of salamization: positive divided by two equals negative.
Iwamoto Y
Diabet Med; 1997 Nov; 14(11):994. PubMed ID: 9400931
[No Abstract] [Full Text] [Related]
31. Accelerated hypertension due to rosiglitazone therapy.
Vikram NK; Misra A; Devi JR
Indian Heart J; 2002; 54(6):733. PubMed ID: 12674195
[No Abstract] [Full Text] [Related]
32. Oral pharmacologic management of type 2 diabetes.
Riddle MC
Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
[TBL] [Abstract][Full Text] [Related]
33. Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
Yang J; Di F; He R; Zhu X; Wang D; Yang M; Wang Y; Yuan S; Chen J
Chin Med J (Engl); 2003 May; 116(5):785-7. PubMed ID: 12875702
[TBL] [Abstract][Full Text] [Related]
34. [Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
MMW Fortschr Med; 2003 Dec; 145(50):54. PubMed ID: 14963975
[No Abstract] [Full Text] [Related]
35. Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Garber A
Diabetes Obes Metab; 2008 May; 10(5):436-7. PubMed ID: 17596200
[No Abstract] [Full Text] [Related]
36. Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes.
Bell DS
Endocr Pract; 2003; 9(1):98-101. PubMed ID: 12917098
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Ballary C; Desai A
J Indian Med Assoc; 2003 Feb; 101(2):113-4, 123. PubMed ID: 12841496
[TBL] [Abstract][Full Text] [Related]
38. Cancer and bone fractures in observational follow-up of the RECORD study.
Jones NP; Curtis PS; Home PD
Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
[TBL] [Abstract][Full Text] [Related]
39. Oral combination therapy for type 2 diabetes.
Charpentier G
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S70-6. PubMed ID: 12324989
[TBL] [Abstract][Full Text] [Related]
40. [Type 2 diabetes. How can the infarction risk be reduced?].
MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
